News >

Prolonging PFS With PARP Inhibitors in Platinum-Sensitive Ovarian Cancer

Caroline Seymour
Published: Thursday, Aug 22, 2019

Alexander Olawaiye, MD, director, Gynecologic Oncology Research Program, UPMCe

Alexander Olawaiye, MD

By blocking PARP, a key enzyme involved in DNA damage repair, investigators have been able to induce synthetic lethality, which in turn has led to dramatic clinical responses for patients with platinum-sensitive ovarian cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication
x